Related Experiment Video
Updated: Jul 11, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Development of potent and selective factor Xa inhibitors
1Departments of Medicinal Chemistry, Structural Chemistry and Enzymology, Axys Pharmaceuticals, Inc., 385 Oyster Point Blvd., 94080, South San Francisco, CA, USA.
Abstract:
The development of potent and selective small molecule inhibitors of factor Xa is described.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacogenomics: Identification of New Drug Targets
Venous Thrombosis III: Interprofessional Care

